Beta blocker versus ivabradine for cardiovascular outcomes among patients with atrial fibrillation.
Postgrad Med J
; 2022 Aug 22.
Article
en En
| MEDLINE
| ID: mdl-37117042
ABSTRACT
PURPOSE:
We conducted a retrospective observational study using Taiwanese insurance records to examine the association between beta blocker (BB)/ ivabradine (IVA) and cardiovascular (CV) outcomes in patients with atrial fibrillation (AF).METHODS:
A total of 1884 AF subjects were enrolled. The propensity score-matching technique was applied to estimate the effect of IVA by accounting for the covariates. The CV outcomes included hospitalisation/rehospitalisation due to acute myocardial infarction, heart failure (HF), haemorrhagic stroke, ischaemic stroke, CV death and all-cause death. Univariate and multivariate Cox proportional hazards regression models were used to estimate crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).RESULTS:
IVA users were found to have a higher risk of HF requiring admission (adjusted HR=2.01; 95% CI 1.67 to 2.42), and all cause death (adjusted HR=1.47; 95% CI 1.11 to 1.94) after adjusting for age, sex, comorbidities and medications.CONCLUSION:
Concerning adverse clinical events, IVA might not be appropriate for patients with AF.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Idioma:
En
Revista:
Postgrad Med J
Año:
2022
Tipo del documento:
Article
País de afiliación:
Taiwán